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Abstract
Introduction The gastrointestinal stromal tumor (GIST) is
the most common mesenchymal tumor of the intestinal
tract, known to be refractory to conventional chemotherapy
or radiation. Its pathogenesis is defined by mutations within
the KIT and PDGFRA gene, which constitutively activate
KIT and PDGFRA oncoproteins, and serve as crucial
diagnostic and therapeutic targets.
Discussion Besides surgery, therapy with imatinib mesylate,
which inhibits KIT kinase activity, represents the other
cornerstone for the treatment of GIST. Still, the only curative
option for GIST is given after complete surgical removal even
in a metastatic setting, but recurrence is common, and the risk
can be defined by surgical factors like incomplete resection,
intraperitoneal rupture, or bleeding and tumor associated
factors like tumor size, mitotic index, or localization.
Conclusion Consequently, adjuvant therapy with imatinib
mesylate or other tyrosine kinase inhibitors is recommen-
ded for high-risk patients after complete resection. For
unresectable and advanced GIST, a partial response or
stable disease can be achieved in about 80% of patients
with imatinib mesylate.
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Introduction
Gastrointestinal stromal tumors (GISTs) represent a wide
clinical spectrum of tumors with different dignity, which
may arise throughout the entire gastrointestinal tract.
They are located typically in the submucosa of the
stomach and the small and large intestines, although
cases arising in the esophagus, greater omentum, and
mesenterial adipose tissue have been described. In the
early literature, these tumors used to be classified as
leiomyomas, cellular leiomyomas, leiomyoblastomas, and
leiomyosarcomas [1], but in the 1960s, electron micro-
scopic studies revealed the lack of typical smooth muscle
differentiation in some of these gastric tumors [2].
Subsequently, leiomyomas, which did not exhibit ultra-
structural characteristics of smooth muscle cells and
lacked immunohistochemical features of Schwann cells
(i.e., no expression of S-100 protein), were classified as
“gastric stromal tumors” by Mazur and Clark in 1983 [3].
Since it has been demonstrated that GIST arise from the
interstitial cells of Cajal [4], which are located in the
submucosal and myenteric plexus of the gastrointestinal
tract, the term GIST is applied to these mesenchymal
tumors arising in the submucosa of the gastrointestinal
tract marking the beginning of a new era. Consequently,
reports published before 1993 dealing with gastric and
intestinal smooth muscle tumors largely describe GIST
[5–7]. The genetic basis of GIST growth is a mutation of
the KIT or PDGFRA gene leading to constitutional
activation of receptor tyrosine kinases, which is the
driving force behind tumor development. In the following
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review, the definition, epidemiology, pathogenesis, mor-
phologic and genetic findings, treatment, and prognostic
factors of GIST will be discussed.
Literature search and data extraction
First, a PubMed search using different search terms
including “gastrointestinal stromal tumors/GIST[S],”was
conducted. All available English written articles were read
in full length. References were then cross-checked to
achieve—to the best of our knowledge—completeness of
the reports to be included in this review.
Definition
GISTs usually present as round, sharply demarcated mass
lesions arising in the submucosal layer of the gastrointes-
tinal (GI) tract (Fig. 1). They are defined as tumors of the
GI tract that are composed of spindle cells, epithelioid, or
occasionally pleomorphic mesenchymal cells and mostly
express the KIT (CD117, stem cell factor receptor) protein
(Fig. 2). GIST have been described to originate from
interstitial cells of Cajal [4] or a stem cell-like subset of
KIT-positive spindle cells around the myenteric plexus [4,
8, 9]. Most of these tumors are strongly and nearly
uniformly KIT positive (70%) and can be histologically
subclassified into eight subtypes, mainly of spindle cell,
epithelioid, or mixed-type differentiation [10]. Although
other tumor entities, such as metastatic melanoma, pulmo-
nary small cell carcinoma, and other types of carcinoma,
angiosarcoma, Ewing sarcoma, mastocytoma, and semi-
noma, may show positive expression of KIT, they are not
classified as GIST [11–14]. Furthermore, true smooth
muscle tumors (leiomyomas and leiomyosarcomas),
schwannomas, and neurofibromas are excluded by the
above-mentioned definition. However, some tumors, which
apply to the morphological criteria for GIST, do not express
KIT. They also typically lack all other marker proteins
employed in the differential diagnosis of GIST [CD34,
PDGFRA, smooth muscle actin (SMA), desmin and S-100
protein], and the classification of these tumors with a “null-
phenotype” is still being discussed. In case of lacking KIT
expression, immunohistochemical staining with PKC theta
[15], PDGFRA [16], or DOG-1 [17] can be of additional
help.
Epidemiology
The annual incidence of GIST is estimated at 10–20/
million, with 20–30% of cases presenting features of
metastasis upon first diagnosis. GISTs typically occur in
individuals above 50 years of age [18–21] at a median age
ranging between 55 and 65 years, including all locations.
GIST is very infrequent in children and only rarely
develops before the age of 40 years. Some series show
equal gender distribution, but others propose a male
predominance [14, 18, 22, 23].
GIST are most commonly located in the stomach (60–
70%), followed by the small intestine (20–30%), colon and
rectum (5%), and esophagus (<5%). Rare cases of primary
GIST located in the greater omentum and mesentery have
also been reported [24], but in these cases of extragas-
trointestinal GIST with extensive involvement of the
abdominal cavity, the primary site of origin may simply
be impossible to determine. GIST may occur sporadically
in pediatric cases, but population-based figures on the
incidence of GIST in children are not available [25–27].
Only few cases with familial GIST have been reported so
far since its first description in 1998 [28–32], and the
inheritance is autosomal dominant. In addition to germ line
KIT mutations, germ line mutations encoding the succinate
dehydrogenase (SDH) subunits B, C, D (SDHB, SDHC, and
SDHD) have been identified in familial GIST recently [33].
Fig. 1 Grossly, gastrointestinal
stromal tumors (GIST) usually
present as round and sharply
demarcated submucosal mass
lesions throughout the gastroin-
testinal tract, as in this case, in the
wall of the stomach (a). They
exhibit a solid, sometimes cystic,
fleshy, tan white cut surface with
occasional areas of hemorrhage
(b) and sometimes ulcerations of
the overlying mucosa
690 Int J Colorectal Dis (2012) 27:689–700
Furthermore, GIST rarely occurs in association with
other tumor syndromes such as neurofibromatosis type 1
[34–36]. Neurofibromatosis-associated GIST are often
multiple within the small intestine [34–36]. Aidan Carney
first described the association of gastric leiomyosarcoma,
extra-adrenal paraganglioma, and pulmonary chondroma,
which was subsequently termed Carney triad [37]. In
addition, adrenocortical tumors and esophageal leiomyoma
were considered components of the triad [38–40] recently.
Furthermore, it was suggested to distinguish an inherited
tumor syndrome comprising GIST and paragangliomas
(Carney–Stratakis syndrome or Carney–Stratakis dyad)
from the classic Carney triad [41].
Pathogenesis and genetics
The central events in the pathogenesis of GIST are the
exclusive mutations of the KIT and PDGFRA gene. The
KIT gene encodes a protein that serves as a receptor for
the growth factor stem cell factor, and the intracellular
domain contains a tyrosine kinase enzyme, which acti-
vates a cascade of activities ultimately causing mitosis.
Mutations in the KIT gene lead to uncontrolled activation
of the tyrosine kinase site and therefore enhanced cell
proliferation [4].
Mutations can be subdivided into primary (i.e., original)
and secondary mutations, the latter developing during the
Fig. 2 On microscopic view,
GIST either show spindle cell
[a hematoxylin–stain (HE)] or
epithelioid differentiation (b),
HE, the latter of which being
most frequent in gastric GIST.
Immunostaining with CD117
(KIT) is characteristically
positive in GIST of either
differentiation (c spindle cell,
d epithelioid). Immunostaining
with PDGFRA is typically
weaker in spindle cell GIST
(e) than in epithelioid GIST
(f) (×100)
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treatment with tyrosine kinase inhibitors and causing
secondary drug resistance. The most common primary
mutations (deletions, point mutations, and duplications)
are being observed in exon 11 (juxtamembrane domain) of
the KIT gene (Fig. 3). The most common mutations in
gastric GIST are duplications in the 3′ region of KIT exon
11, whereas tumors with deletions behave more aggres-
sively than those with point mutations [42]. Furthermore,
patients with KIT mutations involving codons 557–558
have an unfavorable prognosis [43]. In gastric GIST,
PDGFR-alpha mutations are found in up to 20% [25].
Mutations of the KIT kinase domains (i.e., exon 13, 14, and
17) are very rare, and GIST with such mutations show
variable sensitivity to imatinib. Interestingly, secondary
mutations usually occur in these KIT kinase domains in
patients during or after imatinib treatment and lead to
secondary drug resistance. In GIST without KIT mutations,
PDGFRA mutations occur with a frequency of approxi-
mately 30–40%, predominantly in gastric GIST often
leading to primary imatinib resistance [44].
Furthermore, these tumors display typical patterns of
chromosomal gains and losses, including losses at 1p, 14q,
15q, and 22q. Tumor site is associated with distinct
chromosomal imbalances; for instance, gastric GIST show
predominantly losses of 14q, whereas intestinal GIST more
frequently exhibit losses of 15q [45].
Taken together, mutational analysis of GIST serves as an
important tool not only in the diagnostic procedure but also
in the assessment of potential sensitivity and response to the
application of tyrosine kinase inhibitors [42, 46, 47].
Biological behavior and prognostic factors
In general, the risk of progression in completely resected
primary GIST can be predicted by the combination of
mitotic rate, tumor size, and localization (Table 1) [48, 49].
In 2002, Fletcher et al. [49] first proposed a classification
for the estimation of the risk of progression taking into
account mitotic rate and tumor size (centimeters). This
classification was then extended by Miettinen et al. [48]
who recognized that also the tumor site played an important
role and included this criterion in the risk stratification of
GIST in 2006 leading to the current Union for International
CancerControl (UICC) classification (Table 2). However,
the Miettinen–Lasota classification has been validated in a
large dataset, whereas this is not the case for the UICC
classification, thus limiting the clinical applicability of the
latter.
GIST arising in the esophagus are very rare [19, 50]
and are typically localized in the lower third of the
esophagus. The majority of tumors excide 5 cm in size and
display >5 mitoses per 50 high power fields (HPF), but
due to the limited number of cases with documented long-
term follow-up, a definitive risk stratification cannot be
defined yet.
In contrast to esophageal GIST, gastric GIST represent a
large clinic-pathologically complex group and make up the
majority of GIST [21, 51]. Reported tumor size varies from
a few millimeters to >40 cm with a mean size of 6 cm in the
largest reported series [25]. Gastric GIST often shows a
higher frequency of epithelioid morphology and positive
immunostaining for PDGFRA than non-gastric GIST [10].
Interestingly, gastric GIST exhibits a better prognosis than
small intestinal GIST of comparable size and mitotic rate.
Thus, gastric GIST with ≤5 mitoses per 50 HPF and a size
of ≤10 cm have a low risk of distant metastases with <5%
compared to small and large intestinal GIST, which already
show a high risk of progression at the same mitotic rate and
size [25]. GIST of 2 to ≤5 cm size and >5 mitoses per 50
HPF located in the stomach show progression in 10–15%,
similar to tumors >10 cm but with mitotic rates ≤5/50 HPF.
Only 4–5% of GIST are located in the duodenum [52,
53]. Most of these tumors feature spindle cell differenti-
ation and the prognosis of tumors ≤2 cm with ≤5 mitoses
per 50 HPF is excellent. Tumors with a size from >2 to
≤5 cm have a high risk of clinical progression even with
≤5 mitoses per 50 HPF. Patients with duodenal GIST
Fig. 3 Mutational analysis of the KIT and PDGFRA genes has become an important prognostic tool with therapeutic impact as the exemplary point
mutation at codon 557 at KIT exon 11, causing the replacement of the amino acid tryptophan by glycine (c.1669T >G;p.W557G) (arrow)
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exceeding 5 cm or >5 mitoses per 50 HPFs have a high
tumor-related mortality.
The small intestine harbors the second largest group of
GIST with a tumor-related mortality up to 50% [27] and a
higher rate of malignant behavior than gastric GIST [27].
Small intestinal GIST occur at a median age of 59 years
with a male predominance of 55%. In contrast to gastric
GIST, intestinal GIST are mostly spindle cell tumors with
only 5% of epithelioid morphology. Remarkably, the
epithelioid GIST of the small intestine is significantly
linked to a bad prognosis and differs morphologically and
clinically from gastric epithelioid GIST [27]. Whether this
difference results from a different histological subtype or
reflects the morphological manifestation of tumor progres-
sion is not yet defined.
Only 1–2% of GIST are located in the colon. The
prognosis of these tumors can be classified based on mitotic
rates into a favorable and unfavorable group [54–56]. GIST
of the rectum vary from incidental small tumors to huge
tumors, which occupy almost the entire pelvis, and
represent 4% of all GIST. Prognosis is again estimated by
tumor size and mitotic rate. Only small tumors (<2 cm)
with low mitotic rate (<5 per 50 HPF) do not show
evidence of clinical progression. A mitotic rate of >5 per
HPFs results in a metastatic rate of >50% [57].
Outside the gastrointestinal tract, GIST tumors are rare
(<1%), and most of them might represent metastases of GIST
located primarily in the gastrointestinum [58]. These tumors
are commonly designated as extragastrointestinal GIST
(EGIST) [24, 59, 60] and exhibit an overall favorable
prognosis [59, 60], which contradicts the view that they
might be metastases. However, the available data regarding
the prognosis of EGIST are still rather limited. Apart from the
greater omentum, the mesenteric tissue and retroperitoneum,
few cases of EGIST in the rectovaginal space, urinary bladder,
pharynx, and the gallbladder have been reported [61–64].
In summary, the rate of clinical progression, including
risk of metastases and relapse and tumor-related death in
GIST, can be estimated by mitotic rate, size, and location
(Table 1) [25, 27, 48, 52, 57].
Diagnostics
Initial patient evaluation should include a computed
tomography (CT) scan (Fig. 4) of the abdomen and pelvis
Table 1 Risk stratification of
malignant GIST according to
Miettinen et al. [27]
HPF high power fields, n.a. not
available due to small number of
patients
aDefined as rates of metastases
or tumor related death in GIST
bVery small number of cases
cCombined due to small number
of cases
Risk of progressiona
Mitotic rate Tumor size (cm) Stomach Jejunum or leum Duodenum Rectum
≤ 5/50 HPF ≤2 None None None None
>2≤5 Very low Low Low Low
>5≤10 Low Moderate Highc Highbc
>10 Moderate High
> 5/50 HPF ≤2 Noneb Highb n.a. High
>2≤5 Moderate High High High
>5≤10 High High Highc Highc
>10 High High
Table 2 UICC classification,
seventh edition (2010)
Staging for intestinal GIST can be
applied to GISTs in less common




Mitotic rate Tumor size (cm) T N M UICC stage
Gastric GIST Intestinal GIST
Lowa ≤2 1 0 0 IA I
>2≤5 2 0 0 IA I
>5≤10 3 0 0 IB II
>10 4 0 0 II IIIA
Highb ≤2 1 0 0 II IIIA
>2≤5 2 0 0 II IIIB
>5≤10 3 0 0 IIIA IIIB
>10 4 0 0 IIIB IIIB
Any Any 1 0 IV IV
Any Any 1 IV IV
Int J Colorectal Dis (2012) 27:689–700 693
without chest CT because lung metastases are extraordi-
narily rare. CT scan of primary GIST typically display
exophytic tumors, which are >5 cm and enhance inhomo-
geneously [65]. Endoscopic ultrasound might be of addi-
tional value, but biopsy is not mandatory prior to surgery,
except to rule out differential diagnoses like lymphoma or
other malignant or benign neoplasms. Establishing a
histological diagnosis is essential when planning neo-
adjuvant therapy and in the metastatic setting, where
surgery is not the first treatment of choice. Biopsies can
either be taken endoscopically (deep biopsy reaching the
muscularis layer) or as core needle biopsies (ultrasound or
CT guided). With endoscopic techniques, GIST can be
visualized as a submucosal protruberance, commonly with
a central ulceration [66]. Especially in gastric GIST,
endoscopic ultrasound (Fig. 5) is of additional value in
the diagnostics of GIST because it differentiates the
different layers of the gastric wall allowing the GIST to
be assigned to the muscle layer.
Priciples of therapy
Role of surgery
Still, only complete surgical resection of GIST is curative.
GIST rarely metastasize to lymph nodes [67–70] and
therefore regional lymphadenectomy is generally not
required. Furthermore, organ-sparing resection (segmental
resection, etc.) is oncologically appropriate and should thus
be aimed for. The primary goal is to remove the tumor with
tumor free margins since 5-year overall survival in GIST
patients with complete gross resection has been estimated at
42% compared to only 9% overall survival if the excision
was incomplete [70]. GIST can usually be lifted away from
surrounding structures, rarely spread into adjacent organs
and therefore offer an excellent opportunity for laparoscopic
tumor resection with efficacy and recurrence rates similar or
superior to historical open surgical controls [71–74]. When
the tumor attaches to other organs, en bloc resection is
appropriate. Intraperitoneal rupture or bleeding is associat-
ed with a high risk of postoperative recurrence of nearly
100% [43, 75, 76]. Therefore, it is of critical importance
that the GIST, which is soft and fragile in nature, does not
rupture intraoperatively demanding special care while
handling the tumor.
Tyrosine kinase inhibitors
Within the KIT and PDGFRA gene, the mutations are
clustered in four (exons 9, 11, 13, and 17) or three exons
(exons 12, 14, and 18), respectively [77] resulting in
constitutive tyrosine kinase activity. Tyrosine kinase inhib-
itors are able to occupy the active site of the enzyme and
thus prevent the activation and subsequent cell division
[78]. This offers the opportunity of a targeted treatment of
GIST by tyrosine kinase inhibitors, such as imatinib
mesylate (IM, Gleevec®, Novartis, Basel, Switzerland) or
others. Beside imatinib mesylate several other tyrosine
Fig. 4 Abdominal CT scan displaying a gastric GIST
Fig. 5 Endosonography for a
gastric GIST (a) with the
corresponding gastroscopic view
of the tumor (b)
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kinase inhibitors like sunitinib, nilotinib, masatinib, mose-
tanib, sorafenib, regorafinib, and dasatinib [79] are avail-
able. These substances differ in their ability to inhibit one
or several tyrosine kinases.
Side effects
Generally, therapy with tyrosine kinase inhibitors is well-
tolerated and safe. However, one has to be aware of some
side effects and enzymatic interactions, which are listed in
the information and direction of use provided by the
manufacturer. Plasma levels can be influenced by drugs
that are metabolized by the cytochrome P-450 isoform 3A4.
In our experience, clinical side effects mainly include
edema (mostly periorbital), muscle cramps, and gastroin-
testinal side effects. Hematologic side effects include
decreases in hemoglobin levels and leukocyte count.
Generally, therapy does not have to be interrupted, and
treatment is mostly symptomatic [66].
Neoadjuvant therapy
Neoadjuvant therapy with tyrosine kinase inhibitors should
be considered to facilitate R0 resection and allow for a less
morbid operation, especially in duodenal GIST in which
complete surgical resection is sometimes difficult to
achieve [80]. Tumor size and vascularization may be
reduced resulting in a decreased risk of intraoperative
tumor rupture and peritoneal seeding [81–83].
In several studies, the effect of preoperative application
of imatinib mesylate in patients with primary GIST of
different sites was examined. While some authors report
tumor shrinkage in all patients with a median size reduction
of 34% and conclude that, in unresectable or locally
advanced GIST, preoperative imatinib mesylate can be
useful to improve resectability and reduce surgical morbid-
ity [84], others classify the response clinically into three
groups: (1) early responders (up to 70% [80, 85]), (2) those
with stable disease, and (3) those with progressive disease
while on targeted therapy [85]. The impact of preoperative
imatinib therapy depends on the primary KIT and PDGFRA
mutation status. Therefore, early and regular response
control with PET is essential during neoadjuvant treatment,
as non-responders (wild type, unfavorable mutation in KIT
or PDGFRA) must be recognized early. Accordingly,
patients with early radiographic response to imatinib
therapy seem to have a greater probability of R0 resection
and prolonged disease-free survival [85]. In another study,
primary and recurrent metastatic GIST were treated with
preoperative imatinib mesylate, and the 2-year progression
free survival was 83% and 77%, respectively [82].
The duration of neoadjuvant treatment is not completely
defined yet. Eisenberg et al. [81] recommend that the
response of neoadjuvant imatinib mesylate in resectable
GIST should be evaluated early and continuously, and
surgical resection should be offered within 3–6 month to
avoid tumor progression. It is necessary to keep in mind
that secondary mutations may emerge, which may interfere
with drug binding and lead to secondary drug resistance
during the course of therapy [80, 85].
According to the 2011 NCCN guidelines, neoadjuvant
therapy is recommended for GIST that are marginally
resectable or resectable with risk of significant morbidity
(NCCN). The duration for neoadjuvant treatment is
currently discussed, and in therapy responders, a treatment
of 4–6 months has been proposed [86]. Cases that show
progress under preoperative therapy should be treated
following the below-mentioned guidelines for progressive
disease.
Adjuvant therapy
The risk of postoperative recurrence is fairly high in tumors
with the above-stated high-risk features (Table 1) [48].
Without tyrosine kinase inhibitor treatment, the overall 5-
year disease-specific survival rate has been reported as 35%
after surgical resection [26]. Even after complete surgical
resection, the overall 5-year survival rate was only 54% in
metastasized and non-metastasized patients with a median
survival of 19 months in metastatic disease and 12 months
in those with local recurrence [26]. As stated above, high-
risk GIST [48] have a risk of tumor recurrence of up to
66% [51], making it obvious that surgery alone is not
sufficient to provide long-term survival for a vast number
of GIST patients.
The first adjuvant treatment trial was the phase II open-
label, single-arm trial of the American College of Surgeons
Oncology Group (ACOSOG) Z9000 [87]. Patients in this
trial underwent complete gross resection of a KIT-
expressing primary GIST that was at high risk of recurrence
(≥10 cm, tumor rupture, or <5 peritoneal metastases). The
patients with exon 9 mutations of the KIT gene quickly
experienced recurrence once imatinib was stopped (0%
recurrence-free survival at 2 years), and patients with exon
11 mutations showed about 62% recurrence-free survival at
3 years. PDGFRA-mutant patients had the most favorable
results, with about 90% recurrence-free at 3 years. Patients
without detectable mutations (wild type) showed about
77% recurrence-free survival at 3 years. Taken together, this
trial led to the conclusion that imatinib prolongs recurrence-
free survival and is associated with improved overall
survival compared with historical controls [87].
The trial was followed by the phase III double-blind and
placebo-controlled ACOSOG Z9001 trial [88]. Patients had
complete resection of a (c-kit positiv) primary GIST of at
least 3 cm in size, followed by a 1-year adjuvant imatinib
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treatment (400 mg). Recurrence-free survival with imatinib
was 98% versus 83% in the placebo group [88]. Although
adjuvant imatinib therapy was shown to be safe and seemed
to prolong recurrence-free survival compared to placebo
treatment, the overall survival was not different at this time
[89]. This study has led to the accelerated approval by the
Food and Drug Administration (FDA, 12/2008).
In Europe, two other phase III trials are ongoing, and
analyses are awaited for the end of 2011 and 2012. The
EORTC 62024 intergroup trial was designed for patients
with intermediate and high-risk GIST treated with imatinib
(400 mg) or placebo for 2 years with overall survival as the
primary end point. The German-Scandinavian SSG XVIII/
AIO trial was designed for adjuvant treatment (imatinib
400 mg) of high-risk GIST with a treatment duration of 3 or
1 year and recurrence-free survival as the primary end
point. Some data suggest that when interrupted at either 1
or 3 years, relapse consistently can be observed at a median
of 6 months [90]. However, it is still being debated whether
adjuvant treatment will prevent relapse or only delay [90], and
the unknown long-term efficacy and safety profile of
adjuvant imatinib have to be considered in the decision
[91]. The optimal duration of adjuvant imatinib still has to be
determined, and the only available data show the efficacy of
1-year treatment vs. placebo on progression-free survival,
although 1 year of treatment in view of the ACOSOG Z9001
and preliminary results of the SSG XVIII trial may not
suffice. Concerning the development of imatinib resistance
in adjuvant treated GIST, interesting findings within the
BFR14 trial suggest that the time to resistance to imatinib
begins to elapse on the first day of imatinib administration
and is not stopped at imatinib interruption [90]. However,
further studies are being done to examine this observation
and define possible consequences.
The current clinical practice guidelines [92] recommend
surgical resection for limited disease and adjuvant imatinib
therapy as an option for patients with a substantial risk of
relapse (see Table 1). Rupture and intraperitoneal hemor-
rhage have to be considered as metastatic GIST until
proven otherwise.
The optimal duration of adjuvant therapy with tyrosine
kinase inhibitors is still being debated [93]. To define the
patient group that profits most from adjuvant imatinib
treatment, tumor size, mitotic count, mutation type and site,
and the quality of surgery will have to be taken into account
[90]. Furthermore, mutational analysis may select patients
who are more likely to benefit from the treatment. KIT exon
11 mutations show the greatest benefit from adjuvant
treatment with 400 mg imatinib. Of note, KIT exon 11
codon 557/558 deletion/insertion mutations have a more
aggressive clinical behavior [94]. Regarding KIT exon 9
mutations, it has been demonstrated that KIT exon 9 mutated
GIST profit from a higher imatinib dosage in view of
recurrence-free survival [95, 96]. In addition, sunitinib is
beneficial for exon 9 mutated-GIST [97]. Wild-type patients
do not seem to benefit from adjuvant imatinib [47]; however,
in vivo studies evaluating sunitinib [98] and in vitro studies
for nilotinib and dasatinib [79] are promising. As for
PDGFRA-mutated GIST, PDGFRA exon 18 generally
benefits from adjuvant imatinib therapy, with the exception
of PDGFRA exon 18 D842V-mutated GIST [44].
However, all patients in the above-mentioned studies
were treated in a palliative setting, and currently, there is no
published evidence on the different effects of adjuvant
imatinib in GISTs with different mutations.
Palliative therapy
Existing clinical practice guidelines (NCCN, ESMO)
recommend the administration of imatinib for patients with
metastases in the liver or the peritoneum. In the year 2000,
the application of the tyrosine kinase inhibitors imatinib
mesylate was first studied in the palliative setting for
patients with advanced and non-resectable GIST [99].
According to the NCCN guidelines, patients with progres-
sive disease under imatinib treatment can be re-assessed for
surgery. If surgery is not an option, limited and generalized
progression should be distinguished. Limited progression
should be treated either with imatinib at the same or increased
dose; if possible, radiofrequency ablation can be considered.
With further or generalized progress, imatinib at increased dose
or sunitinib (37.5 mg) [97, 100, 101] should be considered. If
the disease progresses despite prior imatinib or sunitinib
therapy, participation in a clinical study, other options, or best
supportive care are advised. Other options include novel
substances such as nilotinib [102], the oral multikinase
inhibitors sorafenib [103, 104], masatinib, dasatinib [105],
and AMG706, the oral antiangiogenic molecule vatalanib
[106], the mTOR-inhibitor RAD 001 and rapamycin [107],
and the protein kinase C-inhibitor PKC 412 [108]. These
substances do not have a label for GIST and can thus be used
only off-label or in a clinical trials. Additionally, re-exposal to
imatinib can be discussed after treatment interruption or
progression under other treatment schedules.
In the future, combination therapies will be discussed. This
might include tyrosine inhibitor combinations as well as
chemotherapy combinations. A recent article showed prom-
ising activity of the combination doxorubicin with imatinib in
heavily pretreated gastrointestinal stromal tumors [109].
The role of surgery in the setting of metastatic GIST is
still being discussed, and data to guide surgical decision
making, such as timing for intervention, are very limited
[93, 110–113]. Some authors propose a positive effect of
surgical debulking for limited progression on kinase
inhibitor therapy in selected cases and in residual disease
upon best clinical response compared with patients treated
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with imatinib alone [93, 110, 111]. However, in the setting
of generalized progression, the role of surgical treatment is
very limited and usually not indicated [93, 111].
Follow-up
According to the ESMO guidelines from 2010, there are no
published data for the optimal routine follow-up policy of
surgically treated patients with localized disease [92]. Metas-
tases are mostly observed in the peritoneum or the liver [92].
The speed at which relapses take place is probably influenced
by the mitotic rate of the tumor. Therefore, risk assessment
based on mitotic count, size, and localization can be helpful
in choosing the individualized follow-up [92]. Since patients
with high risk GIST generally relapse within 2–3 years, and
patients with low-risk may relapse later, the follow-up should
be adapted to tumor criteria [92]. According to the NCCN
guidelines, in the setting of localized disease, contrast-
enhanced abdominal and pelvic CT scan is the technique of
choice for staging and follow-up [114]. In rectal GIST, MRI
should be used, and additional PET or PET-CT/MRI but may
be useful for early detection of tumor response during
neoadjuvant treatment [114]. Even though in Germany,
regular ultrasound exams help to extend the CT intervals,
the ESMO guidelines mention exemplary follow-up schemes:
For intermediate–high-risk patients, a CT routine follow-up
can be done every 3–4 months for 3 years, then every
6 months until 5 and yearly afterwards [92]; for low-risk
tumors, every 6 months for 5 years; and very low-risk GIST
probably do not deserve routine follow-up [92]. We would
however recommend CT intervals of 6 months for high-risk
GIST, with an ultrasound exam at 3 months. After 5 years,
with non-detectable or stable disease, a yearly CT scan should
be sufficient. In our experience, while liver metastases are
well-detected by imaging techniques, peritoneal metastases
become apparent with sub-ileus or ileus symptoms, before
they are depicted in routine imaging. PET-CT might help to
detect the development of early metastases and to distinguish
active tumors from hyaline tumor remnants and facilitates the
planning of surgical interventions [115].
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